San Juan, Puerto Rico – (Thursday, May 7, 2026) – Puerto Rico Governor Jenniffer González-Colón, alongside Secretary of the Department of Economic Development and Commerce Sebastián Negrón Reichard, announced today that, in another strong vote of confidence in Puerto Rico, Amgen has formalized plans to invest an additional $300 million to expand its manufacturing operations in Juncos. The investment further reinforces the Island’s position as the leading biomanufacturing hub in the United States while ensuring a reliable supply of medicines for patients around the world.
The expansion will increase U.S. biologics manufacturing capacity, support workforce retention and development in Puerto Rico, strengthen supply chain resilience, and advance next generation biomanufacturing technologies. With this latest announcement, Amgen’s cumulative investment commitment on the island during this administration now approaches $1 billion, further solidifying Puerto Rico’s role as a strategic advanced manufacturing destination within the United States. The expansion will support the more than 2,300 jobs Amgen currently sustains on the island while also creating new high-value employment opportunities.
Governor Jenniffer González-Colón highlighted the significance of the announcement, stating, “This investment confirms that the policies we have put in place are delivering results. Puerto Rico has more than 60 years of excellence in the biopharmaceutical industry, supported by a highly skilled workforce and world-class infrastructure and Amgen knows that better than anyone. We will continue working to ensure Puerto Rico remains the number one destination for advanced manufacturing in the United States.”
Secretary Sebastián Negrón Reichard underscored the importance of the decision, noting that, “Amgen’s additional $300 million commitment in Juncos is a powerful signal that the future of American biomanufacturing is being built here. Combined with the $650 million previously announced, this represents nearly $1 billion in confidence in our workforce, our capabilities, and our ability to produce life-saving medicines. This is the result of our commitment to building a pro-business jurisdiction where world-class companies like Amgen can grow, invest, and thrive.”
Robert A. Bradway, Chairman and Chief Executive Officer of Amgen, reaffirmed the company’s commitment to Puerto Rico, stating, “Amgen has been a leader in U.S. biomanufacturing for decades, and this investment reflects our continued commitment to building and strengthening American manufacturing. By expanding our operations in Puerto Rico, we are investing in the long-term strength of our domestic supply chain, supporting the retention of American jobs, and ensuring patients have access to the medicines they need.”
Established in Puerto Rico since 1992, Amgen has been part of the Foreign Trade Zone program since 2009 through the Puerto Rico Industrial Development Company (PRIDCO). Over more than three decades of uninterrupted operations, the company has transformed its Juncos facility into one of the largest and most advanced biomanufacturing sites in the world. The facility manufactures biologic medicines distributed to more than 60 countries.
###
